Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor

Angiotensin II (Ang II) is known to be involved in the progression of ventricular dysfunction and heart failure by eliciting cardiac fibrosis. The purpose of this study was to demonstrate whether treatment with an antioxidant compound, edaravone, reduces cardiac fibrosis and improves ventricular fun...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wei-Wei, Bai, Feng, Wang, Jin, Zheng, Rong-Hua, Yang, Li-Wang, James, Erskine A, Zhao, Zhi-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652925/
https://www.ncbi.nlm.nih.gov/pubmed/29081650
http://dx.doi.org/10.2147/DDDT.S144807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652925/
https://www.ncbi.nlm.nih.gov/pubmed/29081650
http://dx.doi.org/10.2147/DDDT.S144807

Ejemplares similares